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Abstract 
Hepatobiliary MRI contrast agents are increasingly being used for liver imaging. In clinical practice, most focal liver 
lesions do not uptake hepatobiliary contrast agents. Less commonly, hepatic lesions may show variable signal 
characteristics on hepatobiliary phase. This pictorial essay reviews a broad spectrum of benign and malignant focal 
hepatic observations that may show hyperintensity on hepatobiliary phase in various clinical settings. In non‑cirrhotic 
patients, focal hepatic observations that show hyperintensity in the hepatobiliary phase are usually benign and 
typically include focal nodular hyperplasia. In patients with primary or secondary vascular disorders, focal nodular 
hyperplasia‑like lesions arise as a local hyperplastic response to vascular alterations and tend to be iso‑ or hyperin‑
tense in the hepatobiliary phase. In oncologic patients, metastases and cholangiocarcinoma are hypointense lesions 
in the hepatobiliary phase; however, occasionally they may show a diffuse, central and inhomogeneous hepatobiliary 
paradoxical uptake with peripheral rim hypointensity. Post‑chemotherapy focal nodular hyperplasia‑like lesions may 
be tricky, and their typical hyperintense rim in the hepatobiliary phase is very helpful for the differential diagnosis with 
metastases. In cirrhotic patients, hepatocellular carcinoma may occasionally appear hyperintense on hepatobiliary 
phase.
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Key points
• In non-cirrhotic patients, FNH and FNH-like lesions 
are likely the most common lesions showing hyperin-
tensity in the HBP.
• Cholangiocarcinoma and some metastases may dem-
onstrate central contrast retention in the HBP due to 
fibrotic stroma.
• In cirrhotic patients, well-differentiated HCC may 
show contrast uptake in the HBP in 9–14% of the 
cases.
Background
Hepatobiliary MRI contrast agents—i.e., gadobenate 
dimeglumine (i.e., Gd-BOPTA, Multihance, Bracco, 
Milan, Italy) and gadoxetate disodium (i.e., Gd-EOB-
DTPA, Eovist or Primovist, Bayer Healthcare Phar-
maceuticals, Whippany, NJ, USA)—are increasingly 
being used for liver imaging. These contrast agents 
are taken up by normal hepatocytes through the 
organic anion transporting polypeptide 1 (OATP1B3) 
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multidrug-resistance-associated proteins (MRP2) on 
the canalicular surface [1]. Compared to gadobenate 
dimeglumine, gadoxetate disodium is administered 
at a lower dose (0.1  mmol/kg vs 0.025  mmol/kg of 
body weights), has greater uptake (50% vs. 3–5%) and 
has earlier onset uptake by the hepatocytes (starting 
from 40 min vs. 60–90 s after contrast injection), which 
results in differences in the enhancement of hepatic 
parenchyma and vessels on portal venous, delayed and 
hepatobiliary phase (HBP), as well as earlier acquisition 
of HBP [2–6].
The lack of normal hepatocytes in most focal liver 
lesions results in the lack of hepatobiliary contrast uptake 
and, therefore, hypointensity of these lesions relatively 
to normal background liver parenchyma in the HBP. 
Less commonly, hepatic lesions may show variable signal 
characteristics (Table 1) on HBP due to increased uptake 
of hepatobiliary contrast agents through OATP1B3 or 
to a delayed central enhancement secondary to retained 
contrast material by the fibrotic stroma (Fig. 1) [7, 8].
This pictorial essay reviews a broad spectrum of benign 
and malignant focal hepatic observations that may show 
hyperintense signal intensity on HBP on MRI in non-
cirrhotic patients, in patients with vascular disorders, in 
oncologic and cirrhotic patients.
Non‑cirrhotic patients
An incidental liver observation detected at imaging in 
an asymptomatic patient without underlying disease is 
benign in 96% of the cases [9]. Among these observa-
tions, those that may show iso- or hyperintensity in the 
HBP are mainly focal nodular hyperplasia (FNH), areas of 
fat sparing in steatotic liver, and, seldom, hepatocellular 
adenomas (HCAs). The likelihood of these observations 
depends on the patient’s on age, gender and risk fac-
tors such as oral contraceptives, steroids, history of gly-
cogenosis [10–17]. Cholangiocarcinoma and metastases 
may show some central enhancement in the HBP phase 
that is, however, typically lower in comparison with the 
background parenchyma [18–23].
Table 1 Observations, mechanism, typical imaging features and  prevalence of  iso‑ or  hyperintensity signal 
characteristics on hepatobiliary phase
Observations Mechanisms Typical imaging features Prevalence of iso- 
or hyperintensity
Non-cirrhotic patients
Focal nodular hyperplasia Overexpression of OATP1B3; sug‑
gested also an increase in well‑
differentiated bile ducts
Iso‑ or hyperintensity; hyperintense 
rim on HBP
97%
Hepatocellular adenomas Overexpression of OATP1B3 Iso‑ or hyperintensity 83%, 19%, 0% and 0% of β‑catenin, 
inflammatory, HNF1α inacti‑
vated, and unclassified HCAs, 
respectively
Fat sparing in steatotic liver Preserved or even increased paren‑
chymal function compared to the 
background steatotic liver
Homogeneous iso‑ or hyperinten‑
sity
Nearly always (no specific data 
available)
Primary or secondary vascular disorders




FNH‑like nodule Equal or overexpression of OATP1B3 Iso‑ or hyperintensity; hyperintense 
rim on HBP
100%
Metastases Retention in fibrotic stroma; aberrant 
expression of OATP1B3
Targetoid appearance No specific data available
Cholangiocarcinoma Retention in fibrotic stroma Targetoid enhancement 42–57%
Cirrhotic patients
Hepatocellular Carcinoma Overexpression of OATP1B3 Homogeneous hyperintensity, 
mosaic pattern, nodule‑in‑nodule 
appearance or peritumoral hyper‑
intensity
8.8–14%
Regenerative or low‑grade dysplas‑
tic nodules
Overexpression of OATP1B3 Homogeneous iso‑ or hyperinten‑
sity
No specific data available
Multiacinar regenerative nodules Overexpression of OATP1B3 Hyperintense rim on HBP No specific data available
Periportal hyperintensity Possible regenerative changes of 
periportal hepatocytes
Bandlike hyperintense areas along 
the portal tracts
3%
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Focal nodular hyperplasia
FNH is the second most common benign liver tumor 
with a prevalence of 0.03–0.9% in the general adult pop-
ulation, with a peak incidence among women between 
30 and 40  years old [24, 25]. FNH is defined as a nod-
ule composed of benign-appearing hepatocytes occur-
ring in a liver that is otherwise histologically normal or 
nearly normal [26]. Although FNH may increase in size 
in 3–15% of cases, these lesions do not evolve to malig-
nancy and their management is conservative [27, 28].
FNHs show iso- or hyperintensity in the HBP rela-
tively to liver parenchyma in the vast majority (97%) of 
cases [10] (Fig.  2), and this is attributed to OATP1B3 
expression equal or higher than that of the background 
liver or to an increase in well-differentiated bile ducts in 
these lesions compared to the surrounding parenchyma 
[29–33].
This typical iso- or hyperintensity of FNH relatively to 
liver parenchyma in the HBP allows the differential diag-
nosis between FNH and HCA—which is hypointense 
relatively to liver parenchyma most of the time—with a 
specificity of 91–100% [10, 11, 34] and a superior accu-
racy compared to other morphological and dynamic vas-
cular criteria alone and in combination [35]; in clinical 
practice, its presence decreases the number of indeter-
minate or inconclusive cases that require biopsy or sur-
gery. Iso- or hyperintensity in the HBP is homogenous 
in 23–59% of cases [33, 36, 37]. The great variability of 
these percentages in the literature may be partially attrib-
uted to the subjective identification of different patterns 
of FNHs in the various studies. For instance, An et  al. 
[36] identified seven different patterns of signal inten-
sity in the HBP; van Kessel [33] used a six-point scale 
to describe FNH intensity as compared to surrounding 
liver parenchyma; Mohajer et al. [37] classified all FNHs 
in only 3 patterns (i.e., uniform uptake, iso- or hyperin-
tense to liver, hyperintense rim with core that is hypoin-
tense relative to liver, or hyperintense rim with core that 
is iso- or hyperintense to liver) while a more recent paper 
identified two patterns for FNH in the HBP, including an 
homogenous or a doughnut-like pattern [38].
A hyperintense rim on HBP with a peripheral hyper-
intensity higher than a central iso- or hypointense area 
is demonstrated in 23–66% of cases (Fig. 3) [29–33, 37]. 
The hyperintense rim on HBP is related at pathology to 
a strong OATP1B3 expression of the hepatocytes in the 
peripheral areas of the lesion, whereas the hepatocytes 
in the central areas, surrounding the thin radial scars, do 
not show such expression [30]. Although the causative 
mechanism of this different OATP1B3 expression is not 
fully understood, some theories have been proposed: Ven 
Kessel et al. [33] showed that FNH with hyperintense rim 
on HBP had fibrous tissue in the lesion center surrounded 
by some inflammation and vascular proliferation with 
Fig. 1 Top row: schematics showing the uptake mechanism of hepatobiliary contrast agents. Bottom row: corresponding schematics of the 
signal characteristics of liver and focal observations. Left column: a uptake in hepatocytes and (b) corresponding signal characteristics in normal 
liver. Middle column: c increased uptake due to overexpression of OATP1B3 and (d) corresponding iso‑ or hyperintense signal characteristics of 
focal observations (from left to right: FNH, nodule with hyperintense rim, hyperintense HCC, HCC with nodule‑in‑nodule architecture and HCC 
with peritumoral hyperintensity). Right column: e increased uptake due to retention in fibrotic stroma or aberrant expression of OATP1B3 and (f) 
representative target imaging appearance (lower row) of intrahepatic cholangiocarcinoma or metastasis
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Fig. 2 A 46‑year‑old woman with focal nodular hyperplasia. Gadoxetate disodium‑enhanced MRI shows a focal nodular hyperplasia that is (a) 
nearly isointense to liver parenchyma in the precontrast T1‑weighted sequence, (b) with marked hyperenhancement (arrow) in the arterial phase, 
(c) mildly hyperintense in the portal venous phase and (d) hyperintense in the hepatobiliary phase
Fig. 3 A 44‑year‑old woman with focal nodular hyperplasia. Gadobenate dimeglumine‑enhanced MRI shows a focal nodular hyperplasia that is (a) 
hypervascular in the arterial phase and (b) demonstrates a hyperintense rim (arrow) in the hepatobiliary phase
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ductular metaplasia, while the lesion periphery consisted 
mainly of well-differentiated preexistent bile ducts with-
out signs of metaplasia, fibrous tissue, or inflammation; 
according to another theory, the reason for this different 
expression could be secondary to a different origin of the 
hepatocytes, with the ones surrounding the central scar 
of FNH originating from periportal venous hepatocytes 
and the ones in the peripheral portion from perivenular 
hepatocytes [29].
Hepatocellular adenoma
HCA is an uncommon benign neoplasm more frequently 
detected in young women with history of oral contra-
ceptive assumption [39, 40] or young men with history 
of anabolic steroids and glycogen storage disease and 
recently more increasing in both gender suffering from 
metabolic syndrome [12, 41]. HCAs warrant close fol-
low-up and surgery in selected cases considering the pos-
sibility of progressive disease [42] and complications (i.e., 
bleeding) for those exceeding 5  cm in diameter despite 
treatment and, therefore, suspected of malignant trans-
formation [27].
Iso- or hyperintensity of HCAs on HBP has been 
reported in a variable percentage, ranging from 0 to 70% 
[6], and this variability is primarily related to the fact that 
HCAs include eight different subtypes showing differ-
ent molecular/genetic background [43]. Hepatocellular 
adenomas are divided into four main subgroups, show-
ing specific immunohistochemical phenotype, molecu-
lar background, imaging findings, clinical settings and 
natural history: HNF1α-inactivated HCA, inflammatory 
HCA, β-catenin activated HCA, and argininosuccinate 
synthase 1-positive/sonic hedgehog HCA [43]. HCA 
without classical steatosis, mixed β-catenin-activated 
and inflammatory HCA and HCA with focal transfor-
mation into hepatocellular carcinoma (HCA–HCC) 
are also described [43]. Mixed β-catenin-activated and 
inflammatory and β-catenin-activated forms have the 
highest risk of malignant transformation due to their 
β-catenin (CTNBB1) exon 3 gene mutation, with a 
reported odds ratio more than 9 [43]. Hepatobiliary con-
trast agent retention in the HBP occurs in 83%, 19%, 0% 
and 0% of β-catenin, inflammatory, HNF1α-inactivated 
and unclassified HCAs, respectively [44], and it is help-
ful to distinguish all higher-risk HCA and HCA–HCC 
with 100% accuracy [45]. Activation of β-catenin protein 
causes uncontrolled hepatocyte proliferation and overex-
pression of OATP1B3 responsible for iso- or hyperinten-
sity on HBP [32, 45, 46].
At pathology, OATP1B3 expression is preserved or 
increased not only in β-catenin–activated HCAs, but 
also in β-catenin–activated-inflammatory HCA and 
HCA–HCC; this latter shows also an increased MRP3 
expression [45]. This information is of translational 
interest as the hyperintensity on HBP of HCAs could 
potentially be helpful in identifying HCAs at high risk 
of malignancy. Specifically, β-catenin–activated HCAs, 
β-catenin–activated-inflammatory HCA and HCA–HCC 
are expected to show a hyperintense signal on HBP, and 
HCA–HCC might show a faster sinusoidal excretion 
because of their increased MRP3 expression [44, 46].
An interesting finding of some studies is the relatively 
high percentage (21–67%) of inflammatory HCAs show-
ing iso-hyperintensity on HBP (Fig. 4), which is in con-
tradiction to the molecular background of these lesions 
[13–16, 32, 46, 47]. However, a possible explanation is the 
presence of marked hepatic steatosis that reduces signal 
intensity of background liver on T1-weighted pre- and 
post-contrast images—including the HBP—and modi-
fies the relative signal intensity of HCAs [32]. Another 
possible reason could be that some HCAs included in 
these studies were in fact mixed β-catenin activated and 
inflammatory HCA.
Fat sparing in steatotic liver
Focal fatty sparing is a common finding in patients with 
diffuse fatty infiltration of the liver [48]. Areas of fat 
sparing in diffuse fatty infiltration are usually located in 
segment 2, caudate lobe, adjacent to gallbladder or may 
surround a liver lesion, and may present in different 
shapes (e.g., geographic, wedge-shaped, nodular) [48]. 
Fat sparing can be recognized on MRI as an area devoid 
of signal drop in the opposed-phase image compared to 
the in-phase. These areas are usually not visible on T2-, 
T1- and diffusion-weighted images and on post-contrast 
phases and may appear hyperintense in the HBP (Fig. 5) 
due to preserved or even increased parenchymal func-
tion [17]. The causative mechanism of focal fatty spar-
ing is usually related to abnormal vascular inflow, due to 
aberrant small veins, arterial perfusion abnormalities or 
reduced portal flow and increased arterial flow in case of 
fatty sparing surrounding focal liver lesions [48].
Patients with vascular liver disorders
Vascular liver disorders—e.g., Budd–Chiari syndrome, 
congenital portosystemic shunts, hereditary hemor-
rhagic telangiectasia, cavernous transformation of the 
portal vein—are associated with the development of 
hepatocellular tumors such as FNH-like nodules (more 
commonly), HCAs and HCC [49–52]. The causative 
mechanisms of hepatocellular lesions in vascular liver 
disorders include all causes of reduced portal venous 
inflow that consequently lead to an increased hepatic 
arterial inflow.
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Fig. 4 A 46‑year‑old woman with clinical history of oral contraceptive use and pathology‑proven hepatocellular adenoma. Gadoxetate 
disodium‑enhanced MRI shows a normal liver characterized by (a) no significant signal drop of hepatic parenchyma in the opposed phase 
compared to (b) the in‑phase and (c) a hepatocellular adenoma (arrow) that shows contrast enhancement in the arterial phase and (d) 
heterogeneous hyperintensity in the hepatobiliary phase
Fig. 5 A 63‑year‑old man with liver steatosis and focal fat sparing area in segment 4. Gadoxetate disodium‑enhanced MRI shows (a) in the 
opposed‑phase and (b) in‑phase images a fat sparing area with similar signal unlike the background liver that has marked signal drop in the 
opposed‑phase sequence. The area of fat sparing is (c) slightly hyperintense (arrow) to the background liver in the hepatobiliary phase
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FNH-like nodules
FNH-like nodules arise as a local hyperplastic response 
to vascular alterations, occurring in about 36% of patients 
with Budd–Chiari syndrome [49, 53].
FNH-like nodules may rarely be observed in patients 
with cirrhosis [54, 55] or can occur de novo after treat-
ment with oxaliplatin, usually after a mean interval of 
about 48 months after treatment and may increase in size 
in 42% of the cases [56]. The prevalence of FNH-like nod-
ules after treatment with oxaliplatin is not known [56, 
57].
FNH-like lesions demonstrate enhancement in the 
arterial phase and persistent enhancement on portal 
venous or delayed phase in most cases; however, washout 
may be occasionally detected and, in these cases, the dif-
ferential diagnosis with HCC is tricky [49, 58].
FNH-like lesions are usually iso- to hyperintense on 
HBP [49] due to equal or higher OATP1B3 expression 
compared with the background liver tissue [7]. In our 
experience, the signal intensity is homogenously iso- to 
hyperintense (Fig.  6) on HBP when lesions are small, 
while it may demonstrate a hyperintense rim—i.e., 
increased uptake in the periphery of the nodule and a 
central hypointense area (Fig.  7)—if the lesion is larger. 
Of note, Mamone et  al. [59] have recently described 
the possibility of FNH-like lesions showing hypointen-
sity on HBP and suggested as a potential explanation, 
either a different OATP1B3 expression in hepatocytes 
or the presence of areas of abnormal hepatic perfusion/
congestion.
In case of FNH-like nodules related to oxaliplatin, 
FNH-like nodules are also usually hyper- or isointense 
to the surrounding liver parenchyma in the HBP, and 
a ring (or doughnut-like) pattern on HBP is observed 
in approximately 50% cases (Fig.  8) [56]. The poten-
tial explanation of the ring pattern on HBP is suggested 
to be similar to that described for FNH-like nodules in 
vascular liver disorders because the causative mecha-
nism of FNH-like nodules after treatment with oxalipl-
atin is considered sinusoidal obstruction syndrome [56, 
57]. FNH-like nodules do not have any risk of malignant 
transformation and, therefore, do not require any follow-
up or treatment. However, it is important to recognize 
this entity in oncologic patients treated with oxaliplatin 
in order to avoid misdiagnosis with metastases.
Considering the challenges in the differential diagnosis 
between FNH-like lesions and HCC, specific diagnosis 
requires extensive clinical, laboratory and imaging work-
up, including follow-up every 6  months if liver lesions 
have features of FNH-like lesions and alpha 1-fetoprotein 
levels are low, or liver biopsy if imaging features are atyp-
ical, if significant changes occur over time or if serum 
alpha 1-fetoprotein becomes elevated [49].
Oncologic patients
Oncologic patients are more likely to have metastases as 
compared to the general population, but benign obser-
vations showing HBP hyperintensity (e.g., FNHs) are 
expected to have the same incidence as in the general 
population [60–63]. Hypervascular benign liver lesions 
may simulate metastases and HBP often allows the dif-
ferential diagnosis (Fig. 9). Iso-hyperintensity on HBP in 
a lesion detected in oncologic patients usually indicates 
benignity.
Fig. 6 A 38‑year old woman with Budd–Chiari syndrome and 
FNH‑like nodule. Gadobenate dimeglumine‑enhanced MRI 
demonstrates a FNH‑like nodule that shows (a) arterial phase 
hyperenhancement (arrow) and (b) hyperintensity in the 
hepatobiliary phase
Fig. 7 A 41‑year‑old man with cavernous transformation of the 
portal vein and FNH‑like nodules. Gadoxetate disodium‑enhanced 
MRI shows two FNH‑like nodules (arrows) that are hyperintense in the 
hepatobiliary phase with central small hypointensity due to a central 
scar
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As discussed above, oncologic patients may show 
FNH-like nodules after chemotherapy, and the diagno-
sis of these lesions benefits from the use of hepatobiliary 
contrast agents.
In oncologic patients, malignant focal liver lesions 
showing variable signal characteristic on HBP include 
metastases (i.e., the most common malignant liver 
tumors overall) and intrahepatic cholangiocarcinomas 
(i.e., the most common primary non-hepatocellular car-
cinoma malignancy in non-cirrhotic liver).
Metastases
Metastases are the most common malignant liver tumors 
[64]. Liver metastases usually originate from primary 
tumor of colon, breast, lung, pancreas or stomach. Liver 
metastases are broadly classified as hypoenhancing and 
hyperenhancing relative to the liver parenchyma on 
hepatic arterial phase. Most liver metastases are hypoen-
hancing and adenocarcinoma from the gastrointestinal 
tract is the most frequent source of these metastases 
[65]. Hyperenhancing metastases typically originate from 
primary neuroendocrine tumors, renal cell carcinoma, 
thyroid carcinoma, choriocarcinoma, and sarcomas. 
Metastases must be differentiated from other benign or 
malignant liver lesions that may occur in these patients.
The use of hepatobiliary contrast agents is particu-
larly important in the evaluation of liver metastases 
because it increases sensitivity for detection of metas-
tases compared to CT or extracellular agents provid-
ing high tumor-to-lesion contrast on HBP [66, 67]. The 
combination of MR with hepatobiliary contrast agents 
Fig. 8 A 40‑year‑old woman with sigmoid adenocarcinoma and liver metastases treated with chemotherapy (XELOX regimen). a 
Contrast‑enhanced CT shows a FNH‑like nodule (arrow) that is hypervascular in the arterial phase. Gadoxetate disodium‑enhanced MRI performed 
2 years later (b) in the arterial phase and (c) hepatobiliary phase shows size increase which raises the suspicion of metastasis. However, the 
hepatobiliary phase (c) demonstrates a hyperintense rim establishing the diagnosis of FNH‑like nodule
Fig. 9 Differential diagnosis of hypervascular lesions in the 
arterial phase in oncologic patients. Top row: 53‑year‑old woman 
with breast cancer and focal nodular hyperplasia. Gadobenate 
dimeglumine‑enhanced MRI demonstrates a focal nodular 
hyperplasia (arrow) that (a) enhances in the hepatic arterial phase 
and (b) is hyperintense in the hepatobiliary phase. Bottom row: 
58‑year‑old man with pharyngeal carcinoma and hepatocellular 
carcinoma. Gadoxetate disodium‑enhanced MRI demonstrates a 
small HCC nodule (arrow) that (c) enhances in the hepatic arterial 
phase and (d) is hypointense in the hepatobiliary phase
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and diffusion-weighted imaging yields better diagnostic 
accuracy and sensitivity in the detection of small liver 
metastasis than each MR scan sequence alone, on both 
per-lesion basis and per-patient basis [68].
Liver metastases are hypointense on HBP due to their 
lack of normal hepatocytes. However, metastases may 
occasionally demonstrate in the HBP central areas of rel-
ative hyperintensity—described as “EOB-cloud enhance-
ment” similarly to cholangiocarcinoma—compared to 
surrounding lesion (rim) hypointensity with a resulting 
target appearance (Fig.  10) [22, 23, 67]. The causative 
mechanism of this phenomenon is still debated; it has 
been suggested to be a slow accumulation of the con-
trast material within the intercellular matrix of the tumor 
[22] or an interstitial diffusion of the hepatobiliary con-
trast agent within areas of necrosis [67]. Another pos-
sible theory is the presence of aberrant expression of 
OATP1B3 in liver metastases as possible explanation of 
the hepatobiliary uptake; however, while Park et al. [69] 
showed an increased expression of aberrant OATP1B3 
(i.e., the protein involved in hepatocyte contrast uptake), 
Wlcek et  al. [70] showed that expression of OATP1B3 
is downregulated while other OATPs are upregulated. 
The target appearance of metastases in the HBP (i.e., 
peripheral hypointense rim compared to central cloud of 
enhancement) resembles the peripheral washout pattern 
occurring in the delayed extracellular phases in 24% of 
metastases [71].
Cholangiocarcinoma
Intrahepatic cholangiocarcinoma is the most common 
primary non-HCC malignancy in non-cirrhotic liver [72]. 
Although the typical pattern of intrahepatic cholangio-
carcinoma on dynamic studies (i.e., irregular peripheral 
enhancement in the hepatic arterial phase and gradual 
centripetal enhancement on following phases) usually 
allows a confident diagnosis, HBP images are useful to 
increase lesion conspicuity and better delineate daughter 
nodules and intrahepatic metastasis [73].
Intrahepatic mass-forming cholangiocarcinomas 
are hypointense on HBP because these lesions lack 
hepatocytes. In 42–57% of these tumors, a target sign 
is demonstrated as a peripheral hypointense rim and a 
diffuse, mainly central and inhomogeneous “EOB-cloud 
enhancement” (Fig. 11) [18–20].
The clinical relevance of the presence of iso- to hyper-
intense areas on HBP within cholangiocarcinomas is 
twofold: first it is helpful for the differential diagnosis 
with scirrhous HCC because scirrhous HCC is typically 
hypointense on HBP [74]; second, it correlates with prog-
nosis, with a significantly lower rate of 5-year survival 
compared to those showing hypointensity on HBP (53% 
vs 87%, respectively; p = 0.048) [19].
Cirrhotic patients
Cirrhotic patients require periodic surveillance for 
HCC screening. Decreased expression of OATP1B3 is 
one of the steps of hepatocarcinogenesis and leads to 
HBP hypointensity [75, 76]. Hyperintensity on HBP in 
a cirrhotic liver usually indicates benignity, but well-
differentiated HCC in cirrhotic patients may also show 
hyperintensity on HBP. Although cholangiocarci-
noma—i.e., the second most common primary hepatic 
malignancy—may show the so-called “EOB-cloud 
enhancement” on HBP, this pattern is uncommon in 
cirrhosis [77], and we hypothesize that this is related to 
the smaller size of this lesions in cirrhosis as compared 
to non-cirrhotic liver and to the heterogeneous fibrotic 
changes of the cirrhotic liver parenchyma.
Hepatocellular carcinoma
Approximately 80–90% of cases of HCCs develop in cir-
rhotic patients [9].
As most HCCs show hypointensity on HBP, the  Liver 
Imaging Reporting And Data System (LI-RADS) consid-
ers hypointensity on HBP an ancillary feature suggest-
ing malignancy and isointensity on HBP an ancillary 
feature suggesting benignity [78]. However, HCCs show 
contrast uptake on HBP in 8.8–14% of the cases [76, 79]. 
A study by Asayama et  al. [80] has reported an unex-
pectedly higher rate of uptake (Fig.  12), but this may 
be attributed to the different definition of uptake on 
HBP in this study (i.e., increase in signal intensity of the 
lesion on HBP compared with the precontrast image). 
Among the HCCs showing hyperintensity on HBP, the 
Fig. 10 A 73‑year‑old man with colon cancer and liver metastases. 
Gadobenate dimeglumine‑enhanced MRI in (a) arterial phase and (b) 
hepatobiliary phase demonstrates two liver metastases with different 
signal characteristics. A metastasis (black arrow) shows homogenous 
arterial phase hyperenhancement with a peripheral hypointense rim 
in the hepatobiliary phase. A second metastasis (white arrow) shows 
peripheral rim enhancement with a peripheral hypointense rim and 
cloud‑like central enhancement in the hepatobiliary phase
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pattern of hyperintensity may be homogeneous, mosaic 
or as nodule-in-nodule in 57%, 29% and 14% of the cases, 
respectively [38]. Particularly, the nodule-in-nodule 
hyperintensity (Fig.  13) has been reported as a marker 
of the hepatocarcinogenesis process that can predate 
the appearance of hyperenhancement in hypovascu-
lar hypointense nodules [81]. This uptake is correlated 
with maintenance of hepatocyte function with upregula-
tion of OATP1B3 and HNF 4α expression [82–84]. Prior 
studies [85–87] suggested that an abnormality in the 
expression or site of MRPs in the hepatocytes may cor-
relate with hyperintensity on HBP, but this theory is still 
controversial.
Recently, Yoneda et al. [88] described a pattern of HCC 
hypointense on HBP showing peritumoral hyperinten-
sity (Fig.  14). This peritumoral hyperintensity on HBP 
may occur in HCC and may surround partially or com-
pletely the lesion, indicating the presence of peritumoral 
hyperplasia with glutamine synthetase and OATP1B3 
expression [88]. The clinical relevance of the peritu-
moral hyperintensity on HBP is the higher incidence of 
microscopic hepatic venous invasion when this finding is 
detected [88].
Regenerative and dysplastic nodules
Cirrhosis-associated regenerative nodules are innumer-
able well-defined nodules scattered within cirrhotic 
parenchyma, surrounded by scar tissue and typically 
measuring 1–15 mm in diameter [26].
Regenerative nodules are well-defined regions of 
parenchyma made of hyperplastic hepatocytes that often 
contain ductular proliferation and are a response to 
Fig. 11 A 71‑year‑old woman with cholangiocarcinoma. Gadoxetate disodium‑enhanced MRI shows an intrahepatic mass‑forming 
cholangiocarcinoma with (a) continuous rim enhancement on hepatic arterial phase and (b) a target pattern on hepatobiliary phase with 
peripheral hypointense rim (arrow) and inhomogeneous contrast media uptake with a central enhancing area (asterisk) likely related to fibrous 
stroma
Fig. 12 A 65‑year‑old patient with HCV‑related cirrhosis and hepatocellular carcinoma. Gadobenate dimeglumine‑enhanced MRI shows an 
HCC with (a) arterial phase hyperenhancement (arrow) in the arterial phase, (b) non‑peripheral washout in the portal venous phase and (c) 
iso‑hyperintensity in the hepatobiliary phase surrounded by a non‑enhancing capsule
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necrosis, altered circulation or other stimuli. They may 
contain one (monoacinar) or multiple (multiacinar) por-
tal tracts. Monoacinar nodules are usually 0.1–10  mm 
in diameter, while large multiacinar nodules are usually 
5–15  mm in diameter [26]. These nodules show similar 
uptake of gadoxetate disodium to the surrounding liver 
tissue and thus appear isointense. However occasionally 
they may appear hyperintense when compared to the 
background tissue. Although the exact mechanism is still 
unknown, possible explanations include overexpression 
of OATP1B3 or down-regulation of MRP3 (Fig. 15) [26].
Dysplastic nodules are observed in up to 25% of cir-
rhotic patients [89]. Low- and high-grade dysplastic 
nodules commonly show iso- or hyperintensity relative 
to the surrounding liver in the HBP due to preserved 
OATP1B3 expression, but one-third of high-grade dys-
plastic nodules may be mildly hypointense [76].
Multiacinar regenerative nodules
Multiacinar regenerative nodules with hyperintense 
rim on HBP develop in about 6% of cirrhotic patients, 
being more common in HBV-related cirrhosis than 
in HCV-related cirrhosis [80]. These lesions are usu-
ally multiple, do not show any arterial phase hyperen-
hancement, and may demonstrate hyperintensity on 
T2-weighted and diffusion-weighted images in 36% and 
Fig. 13 A 72‑year‑old man with HCV‑related cirrhosis. Gadoxetate disodium‑enhanced MRI shows a lesion with (a) arterial phase 
hyperenhancement and (b) nodule‑in‑nodule architecture with a smaller inner hyperintense nodule (arrow) within a larger outer hypointense 
nodule in hepatobiliary phase
Fig. 14 A 55‑year‑old man with HCV‑related cirrhosis and multiple HCCs. Gadoxetate disodium‑enhanced MRI shows an HCC mass in the caudate 
lobe with (a) arterial phase hyperenhancement in the arterial phase, (b) non‑peripheral washout in the portal venous phase and (c) hypointensity in 
the hepatobiliary phase with peripheral hyperintensity (arrow), suggesting microvascular invasion
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24% of the cases, respectively, mainly in the central area. 
These nodules may show an hyperintense rim on HBP 
with a doughnut-like appearance (Fig. 16) [90]. The rea-
son of hyperintensity in the HBP compared to the sur-
rounding regenerative nodules may be probably due to 
more hyperplastic change than surrounding monoaci-
nar cirrhotic nodules [90]. At pathology, these lesions 
may correspond to multiacinar cirrhotic nodules in the 
International Working Party classification [26, 90]. Con-
sidering the lack of malignant potential of multiacinar 
regenerative nodules, these lesions do not require further 
investigations and can be managed conservatively [90].
Periportal HBP hyperintensity
Patients with various hepatobiliary diseases (e.g., liver 
cirrhosis, autoimmune hepatitis, primary sclerosing 
cholangitis, primary biliary cirrhosis and idiopathic 
portal hypertension) may show periportal hyperinten-
sity in the HBP in 3% of cases (Fig.  17) [91]. Periportal 
hyperintensity in the HBP is defined as relatively higher 
enhancement bandlike areas along the portal tracts 
which take the form of a periportal ring or tramline and 
lower enhancement of the remaining areas of the liver in 
the HBP [91, 92]. The width of the hyperintense part may 
vary from less than 2  mm in the mild pattern to more 
than 3 mm in the severe pattern [88], and periportal HBP 
hyperintensity corresponds to periportal hyperintensity 
on T2-weighted images in 37% of the cases [92].
The causative mechanism and the clinical relevance 
of this imaging finding are still unclear. In patients with 
hepatic disorders such as primary biliary cirrhosis and 
idiopathic portal hypertension, it has been suggested that 
the periportal HBP hyperintensity is related to regenera-
tive changes of periportal hepatocytes, which lead to a 
relatively increased uptake of the hepatobiliary contrast 
agent compared to the damaged background liver [91]. 
Onishi et al. [82] have also suggested that in patients with 
periportal hyperintensity in both HBP and T2-weighted 
images, the imaging finding indicates periportal edema 
which reflects the layer of loose connective tissue sur-
rounding the portal veins expanded by inflammation or 
other conditions; consequently, periportal HBP hyperin-
tensity could be considered as delayed enhancement of 
the periportal loose connective tissue in these patients.
Practical tips based on the clinical setting
Choice of the contrast agent based on clinical setting
In current practice, the use of extracellular contrast 
agents usually allows to determine the diagnosis of most 
focal liver lesions and should be favored as first imaging 
approach for the characterization of focal liver lesions 
and as baseline and follow-up imaging in oncologic 
patients. When the lesion is deemed indeterminate in 
studies with extracellular agents, the adoption of hepa-
tobiliary MRI contrast agents is particularly relevant for 
the differential diagnosis between FNH and hepatocel-
lular adenoma in the non-cirrhotic liver [11, 34–36] and 
between FNH-like nodules and HCC or metastases in 
vascular liver diseases and oncologic patients, respec-
tively [22, 23, 53, 57–59, 67, 68]. In oncologic patients, 
hepatobiliary MRI contrast agents increase sensitivity for 
the detection of metastases as compared to extracellular 
agents [67, 68], and this is particularly relevant in patients 
with hepatic steatosis following chemotherapy [93] or 
for a complete staging in patients with colon cancer that 
are indicated surgery to uncover small liver metastases 
prior to surgery. Finally, in cirrhotic patients with prior 
history of HCC, HBP images are helpful to identify the 
loss of OATP8 expression in hypervascular lesions lack-
ing washout to identify their progression toward malig-
nancy [75–78] and to differentiate between malignancy 
and other benign entities such as regenerative nodules or 
multiacinar regenerative nodules that in some cases may 
pose diagnostic challenges.
Diagnostic algorithm
When a focal liver observation shows iso- or hyperinten-
sity in the HBP, our imaging evaluation should consider 
the clinical setting, the pattern of iso- or hyperintensity 
in the HBP and the information provided by extracellular 
images and T1-, T2-, and diffusion-weighted images.
A nodule showing a doughnut-like hyperintense pat-
tern in the HBP usually indicates FNH in healthy patients 
[10, 11, 24, 32–39], FNH-like nodules in patients with 
vascular disease [50–54] or in oncologic patients after 
oxaliplatin therapy [56, 57] or multiacinar regenerative 
nodules in cirrhotic patients [90].
Fig. 15 A 43‑year‑old man with HCV‑related cirrhosis and multiple 
cirrhotic regenerative nodules. Gadoxetate disodium‑enhanced MRI 
shows multiple cirrhotic regenerative nodules that are hyperintense 
on hepatobiliary phase
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In case of a nodule showing central uptake of con-
trast agent in the HBP due to fibrotic content, imaging 
assessment should be based on extracellular phases: 
If the lesion shows irregular peripheral enhancement 
in the hepatic arterial phase and gradual centripetal 
enhancement on following phases, the diagnosis of 
intrahepatic cholangiocarcinoma is favored because 
this entity may show central uptake in 42–57% of cases 
[18–20]; if the patient has a history of malignancy and 
a target rim appearance on post-contrast phases, the 
lesion is suspicious for metastasis although central 
Fig. 16 A 71‑year‑old man with HCV‑related cirrhosis and multiacinar cirrhotic nodules. Gadoxetate disodium‑enhanced MR shows multiple 
multiacinar cirrhotic nodules that are (a) isointense to surrounding liver parenchyma in the precontrast T1‑weighted sequence and (b) in the 
hepatic arterial phase, (c) show enhancement in the portal venous phase due to early uptake of hepatobiliary contrast and (d) are hyperintense in 
the hepatobiliary phase
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uptake in the HBP is not a common imaging presenta-
tion of liver metastases [22, 23, 67].
In case of iso- or hyperintense nodules on HBP lack-
ing a doughnut-like pattern or central uptake, our diag-
nostic approach should be based on the following three 
scenarios:
1 if the lesion shows lack of signal drop on opposed 
phase compared to in-phase images in a steatotic 
liver and is not visible on T2- and T1- and diffusion-
weighted images and extracellular phase, the diagno-
sis of fat sparing in steatotic liver is favored [17, 48];
2 in healthy or oncologic patients, if the lesion is highly 
hypervascular on arterial phase, and nearly isoin-
tense to liver parenchyma on T2-, T1- and diffusion-
weighted images and extracellular phase, the diag-
nosis of FNH or FNH-like lesion should be favored, 
respectively;
3 in cirrhotic patients, our imaging evaluation should 
be aimed at excluding the presence of the small pro-
portion of HCC that may show hyperintensity in 
the HBP; therefore, radiologists should first analyze 
extracellular phases, then should assess if the lesion 
contains intracellular fat on dual phase images and 
intensity on T1-, T2- and diffusion-weighted images. 
In case of lack of worrisome features for HCC (e.g., 
arterial phase hyperenhancement and washout on 
portal venous or delayed washout, fat content within 
lesion, hyperintensity on T2-weighted images or dif-
fusion restriction) and the presence of hyperinten-
sity on pre-contrast T1-weighted images, and if the 
lesion is less than 1  cm, the hyperintensity on HBP 
may indicate the presence of regenerative or low-
grade dysplastic nodules.
In addition to the above considerations and prior to 
any decision on patient management, it is important to 
investigate whether the patient has any prior cross-sec-
tional imaging available and to compare all prior exam-
inations, particularly the oldest available one, with the 
current examination, in order to assess for lesion sta-
bility in size or changes of imaging presentations over 
time.
If the lesion showing iso- or hyperintensity on HBP is 
suspicious for hepatocellular adenomas, biopsy should 
be indicated to assess if the lesion has the β-catenin 
mutation because β-catenin hepatocellular adenomas 
are indicated to surgery due to their risk of malignant 
transformation [27, 43–45]. If the lesion is suspicious 
for malignancy (i.e., HCC, cholangiocarcinoma or 
metastases) but without a definitive imaging diagnosis, 
biopsy should be indicated to allow for a better patient-
tailored management.
In conclusion, the presence of hyperintensity on HBP 
may be useful for the diagnosis of numerous benign and 
malignant hepatic masses based on knowledge of the 
clinical setting. Indeed, FNH and FNH-like lesions are 
likely the most common lesions showing hyperinten-
sity on HBP in patients without cirrhosis. In cirrhotic 
and in oncologic patients, well-differentiated HCC are 
usually hypointense on HBP but may show hyperinten-
sity in the HBP in about 9–14% of cases, while cholan-
giocarcinoma and some metastases may demonstrate 
variable inner signal characteristics with a peripheral 
rim of hypointensity. In such scenarios, malignancy 
must be ruled out before considering the diagnosis of 
a benign condition, and the use of hepatobiliary MRI 
contrast agents proves to be particularly useful. Finally, 
a histopathological examination may be required to 
resolve challenging cases.
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